StemEx is an expanded stem cell product in development through a joint venture with Teva as an alternative allogeneic therapy for patients with blood cancers such as leukemia and lymphoma who could be cured by bone marrow transplantation but for whom there is no matched bone marrow donor available. Results from the ongoing registrational study are expected by the end of 2012, and market launch of StemEx is projected for 2013. StemEx comprises a graft of expanded stem/progenitor cells derived from a single umbilical cord blood unit, and transplanted by IV administration together with the remaining cells from the same cord blood unit. Gamida Cell says that in contrast with competing cord blood-derived products in development that use two units of blood, StemEx should be significantly less expensive. The firm is currently looking for a strategic partner for global commercialization of the product.